INT204929

From wiki-pain
Revision as of 12:48, 24 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.08
First Reported 2003
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 18
Total Number 18
Disease Relevance 4.74
Pain Relevance 0.70

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (IL33) extracellular region (IL33)
Anatomy Link Frequency
gray matter 3
D17 1
plasma 1
IL33 (Homo sapiens)
Pain Link Frequency Relevance Heat
imagery 54 91.44 High High
Bioavailability 3 89.76 High High
amygdala 108 88.96 High High
cva 4 87.16 High High
Duloxetine 36 81.68 Quite High
Desipramine 9 78.40 Quite High
abdominal pain 8 76.00 Quite High
Inflammation 11 72.20 Quite High
depression 168 66.84 Quite High
Pain 24 56.20 Quite High
Disease Link Frequency Relevance Heat
Handedness 132 99.96 Very High Very High Very High
Disease Progression 8 99.80 Very High Very High Very High
Mouth Disease 65 99.74 Very High Very High Very High
Hepatitis 48 96.80 Very High Very High Very High
Gastroenteritis 41 93.28 High High
Infection 42 87.72 High High
Hemorrhage 4 87.16 High High
Viral Infection 32 86.92 High High
Heart Rate Under Development 4 86.52 High High
Disorder Of Lipid Metabolism 18 85.52 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
DVS sustained release was considered safe in healthy volunteers up to a single dose of 750 mg27 and was well tolerated in multiple doses up to 450 mg.28 The plasma protein binding of DVS is low (30%) and is independent of drug concentration.
DVS Binding (binding) of in plasma
1) Confidence 0.08 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695227 Disease Relevance 0.06 Pain Relevance 0.31
Data pooled from 7 clinical trials, showed that treatment with DVS was associated with small mean decreases in weight in the short term (1 kg), which persisted up to 6 months with a small mean increase (<1 kg) and was comparable to placebo.46
DVS Binding (treatment) of
2) Confidence 0.06 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695227 Disease Relevance 0.31 Pain Relevance 0
The change on HAM-D17 total score from baseline was greater for DVS than for placebo, with a magnitude of effect = ?
DVS Binding (greater) of in D17
3) Confidence 0.06 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695227 Disease Relevance 0.42 Pain Relevance 0.03
Four deaths (two HFMD and two non-HFMD cases) were associated with HEV71.
HEV71 Binding (associated) of associated with mouth disease
4) Confidence 0.03 Published 2003 Journal Emerging Infectious Diseases Section Body Doc Link PMC2873753 Disease Relevance 1.83 Pain Relevance 0.04
These mutants were found to lack the ability to interact with HEV-neutralizing monoclonal antibody, mAb 8C11 (Figure 5).
HEV Binding (interact) of
5) Confidence 0.03 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2714988 Disease Relevance 0 Pain Relevance 0
Taken together the presence of neutralizing antibody binding sites of HEV on E2s, and the shape of the dimer, we suggest that E2s is present on the surface protrusions of HEV shown in the electron microscopic structure [5].
HEV Binding (binding) of
6) Confidence 0.03 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2714988 Disease Relevance 0.06 Pain Relevance 0
To verify that the dimerization of E2s is crucial for the host interaction of HEV, several mutations on dimer interface regions of E2/E2s were carried out (Figures 5 and 6), and their roles in destabilizing the dimer formation were studied.
HEV Binding (interaction) of
7) Confidence 0.02 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2714988 Disease Relevance 0.25 Pain Relevance 0
HEV antibody recognition and E2s
HEV Binding (recognition) of
8) Confidence 0.02 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2714988 Disease Relevance 0.07 Pain Relevance 0
Moreover, two of 13 linear epitope-reactive antibodies and 15 of 20 conformational determinant -reactive antibodies can bind genotype I and/or genotype IV HEV.
HEV Binding (bind) of
9) Confidence 0.02 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2714988 Disease Relevance 0 Pain Relevance 0
Monoclonal antibodies reactive against the abovementioned regions bind to live HEV, and at least two monoclonal antibodies (8C11 and 8H3) could neutralize the infectivity of HEV [8].
HEV Binding (bind) of
10) Confidence 0.02 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2714988 Disease Relevance 0.08 Pain Relevance 0
Neutralizing antibodies such as 8C11 and 8H3 bind with native HEV [8], as well as with the dimeric form of E2 constructs [6],[19].
HEV Binding (bind) of
11) Confidence 0.02 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2714988 Disease Relevance 0.26 Pain Relevance 0
This article reports the crystal structure of the HEV capsid protein domain E2s (protruding domain), along with functional studies, which illustrate the tight homodimeric state of E2s and that dimerization is essential for both HEV–host interactions and disease progression.
HEV Binding (interactions) of associated with disease progression
12) Confidence 0.02 Published 2009 Journal PLoS Pathogens Section Abstract Doc Link PMC2714988 Disease Relevance 0.84 Pain Relevance 0.11
Together, gender, HEV, and gender × HEV interaction were able to account for about 60% of the individual variation in measures of gray matter volume.
HEV Binding (interaction) of in gray matter
13) Confidence 0.01 Published 2007 Journal Behav Brain Funct Section Body Doc Link PMC1820787 Disease Relevance 0 Pain Relevance 0
Together, gender, HEV, and gender × HEV interaction were able to account for about 60% of the individual variation in measures of gray matter volume.
HEV Binding (interaction) of in gray matter
14) Confidence 0.01 Published 2007 Journal Behav Brain Funct Section Body Doc Link PMC1820787 Disease Relevance 0 Pain Relevance 0
Overall, the interaction between gender and HEV had an eta-squared of 0.39 on total GMV.
HEV Binding (interaction) of
15) Confidence 0.01 Published 2007 Journal Behav Brain Funct Section Body Doc Link PMC1820787 Disease Relevance 0 Pain Relevance 0
There was a strong interaction between HEV-laterality and gender, which together accounted for 60% of individual variability in total grey matter volume (GMV).
HEV Binding (interaction) of in grey matter associated with handedness
16) Confidence 0.01 Published 2007 Journal Behav Brain Funct Section Abstract Doc Link PMC1820787 Disease Relevance 0.44 Pain Relevance 0.04
However, there were even more marked interactions between HEV and gender.
HEV Binding (interactions) of
17) Confidence 0.01 Published 2007 Journal Behav Brain Funct Section Body Doc Link PMC1820787 Disease Relevance 0.06 Pain Relevance 0
In contrast, direction of HEV, gender, and their interaction accounted for up to 60% of the variance.
HEV Binding (interaction) of
18) Confidence 0.01 Published 2007 Journal Behav Brain Funct Section Body Doc Link PMC1820787 Disease Relevance 0.07 Pain Relevance 0.16

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox